- Imugene (IMU) receives a South Korea patent grant for its HER-Vaxx Immunotherapy
- The patent will protect the composition and method of the product to 2036
- Importantly, South Korea is a selected country to conduct the nextHERIZON Phase 2 clinical trial in 2022
- South Korea has one of the highest incidence rates of gastric cancer around the world, with approximately one in five cases considered HER2 positive
- On the market this morning, Imugene is down 2.56 per cent and trading at 38 cents per share
Imugene (IMU) has received a South Korea patent grant for its HER-Vaxx immunotherapy.
HER-Vaxx is a b-cell activating immunotherapy designed to treat tumours that over-express the Her-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.
The patent will protect the composition and method of the product to 2036.
Importantly, South Korea is a selected country to conduct the nextHERIZON Phase 2 clinical trial in 2022. This study is a combination of HER-Vaxx with chemotherapy or pembrolizumab.
South Korea has one of the highest incidence rates of gastric cancer around the world, with approximately one in five cases considered HER2 positive. Approximately 75 per cent of all gastric cancer diagnoses are in Asia.
Speaking on the patent rant is Managing Director and CEO Leslie Chong.
“Attaining the key South Korean patent, on top of gaining protection in Japan and China in 2021, is a very important milestone,” Ms Chong said.
“This will protect HER-Vaxx in the world’s largest HER-2 positive gastric cancer markets until 2036.”
On the market this morning, Imugene was down 2.56 per cent and is trading at 38 cents per share at 10:21 am AEDT.